Breaking News Instant updates and real-time market news.

AMGN

Amgen

$184.86

-1.14 (-0.61%)

12:23
06/23/18
06/23
12:23
06/23/18
12:23

Amgen's Repatha 'significantly reduced' LDL-C, non-HDL-C in Type 2 diabetes

Amgen announced new data that show Repatha, or evolocumab, significantly reduced low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. BANTING was a dedicated study evaluating the efficacy of Repatha, in lowering LDL-C and improving other lipid levels in patients with Type 2 diabetes. In addition to meeting criteria for hypercholesterolemia or mixed dyslipidemia, patients in the trial had varying degrees of glycemic control. Data were presented at the American Diabetes Association 78th Annual Scientific Sessions. Results from the BANTING study show that in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, the addition of Repatha to background statin therapy resulted in significant reductions in LDL-C levels. Type 2 diabetes is often associated with dyslipidemia, a condition characterized by low "good" cholesterol or HDL-C and elevated "bad" cholesterol or LDL-C. In addition to producing significant reductions in LDL-C levels, the addition of Repatha to background statin therapy enabled most patients to reach LDL-C levels recommended by current guidelines. The majority of patients in the Repatha group reached LDL-C levels of less than70 mg/dL as recommended by the American College of Clinical Endocrinologists for patients with Type 2 diabetes and one or more risk factors. Treatment with Repatha was also associated with a significantly higher percentage of patients achieving the greater than or equal to 50% reduction in LDL-C levels recommended by the American College of Cardiology and the American Heart Association. Repatha also reduced several other lipid parameters, including non-HDL-C. These results are consistent with results from previous Phase 3 studies demonstrating Repatha's efficacy in reducing LDL-C and non-HDL-C levels in patients with Type 2 diabetes independent of glycemia, insulin use, renal function and cardiovascular disease status at baseline. The safety profile in BANTING was consistent with the established safety profile of Repatha.

AMGN Amgen
$184.86

-1.14 (-0.61%)

06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/22/18
MSCO
06/22/18
NO CHANGE
Target $200
MSCO
Overweight
Amgen may be pressured by IMS restatement for Aimovig, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that IMS announced that it has overstated the mail order volume for Amgen's Aimovig and will amend its mail order method with this week's data and restate prior weeks next Friday. Preliminary figures indicate the restatement will lower overall total prescriptions by about 27%, said Harrison. He would expect pressure on Amgen shares given the perception negative, though he still thinks initial Aimovig demand is robust, Harrison tells investors. He keeps an Overweight rating and $200 price target on Amgen shares.

TODAY'S FREE FLY STORIES

HWC

Hancock Whitney Corporation

$48.35

-0.1 (-0.21%)

17:03
07/17/18
07/17
17:03
07/17/18
17:03
Earnings
Hancock Whitney Corporation reports Q2 adjusted EPS 96c, consensus 95c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

MEOH

Methanex

$71.15

1.4 (2.01%)

17:03
07/17/18
07/17
17:03
07/17/18
17:03
Hot Stocks
Methanex reaches long-term pact for natural gas supply to New Zealand ops »

Methanex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

17:01
07/17/18
07/17
17:01
07/17/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Texas Instruments »

Texas Instruments down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

RNST

Renasant

$45.06

0.05 (0.11%)

17:01
07/17/18
07/17
17:01
07/17/18
17:01
Earnings
Renasant reports Q2 EPS 74c, consensus 74c »

"We are pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

16:59
07/17/18
07/17
16:59
07/17/18
16:59
Earnings
Texas Instruments reports Q2 EPS $1.40, consensus $1.31 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

DERM

Dermira

$10.57

-0.16 (-1.49%)

16:57
07/17/18
07/17
16:57
07/17/18
16:57
Hot Stocks
Breaking Hot Stocks news story on Dermira »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$72.66

0.38 (0.53%)

16:53
07/17/18
07/17
16:53
07/17/18
16:53
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NLY

Annaly Capital

$10.42

0.04 (0.39%)

, MTGE

MTGE Investment

$19.70

0.05 (0.25%)

16:46
07/17/18
07/17
16:46
07/17/18
16:46
Hot Stocks
Annaly Capital extends exchange offer to acquire MTGE Investment »

Annaly Capital Management…

NLY

Annaly Capital

$10.42

0.04 (0.39%)

MTGE

MTGE Investment

$19.70

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

16:42
07/17/18
07/17
16:42
07/17/18
16:42
Hot Stocks
Texas Instruments CEO Brian Crutcher resigns, Rich Templeton to succeed »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CSX

CSX

$64.42

0.46 (0.72%)

16:41
07/17/18
07/17
16:41
07/17/18
16:41
Hot Stocks
Breaking Hot Stocks news story on CSX »

CSX advances 3.2% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WTFC

Wintrust Financial

$88.40

0.25 (0.28%)

16:40
07/17/18
07/17
16:40
07/17/18
16:40
Earnings
Wintrust Financial reports Q2 EPS $1.53, consensus $1.44 »

Edward J. Wehmer,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

UBNK

United Financial

$17.40

-0.07 (-0.40%)

16:39
07/17/18
07/17
16:39
07/17/18
16:39
Earnings
United Financial reports Q2 EPS 31c, consensus 30c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

16:38
07/17/18
07/17
16:38
07/17/18
16:38
General news
API crude inventories for week of July 13 »

API reports that crude…

CASI

Casi Pharmaceuticals

$7.26

-0.215 (-2.88%)

16:38
07/17/18
07/17
16:38
07/17/18
16:38
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHAK

Shake Shack

$66.86

1 (1.52%)

16:37
07/17/18
07/17
16:37
07/17/18
16:37
Hot Stocks
Shake Shack plans to expand to Manila in spring 2019 »

Shake Shack said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 07

    Aug

  • 08

    Aug

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

16:36
07/17/18
07/17
16:36
07/17/18
16:36
Hot Stocks
Breaking Hot Stocks news story on Sonic Automotive »

Sonic Automotive down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

16:34
07/17/18
07/17
16:34
07/17/18
16:34
Earnings
Sonic Automotive sees Q2 adjusted cont ops EPS 32c-36c, consensus 49c »

Sonic Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOPE

Hope Bancorp

$17.52

-0.05 (-0.28%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Hope Bancorp raises quarterly dividend to 14c per share from 13c »

Hope Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 07

    Nov

NTRS

Northern Trust

$105.64

0.18 (0.17%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Northern Trust approves new stock repurchase program of 25M shares »

Northern Trust announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CSX

CSX

$64.42

0.46 (0.72%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Earnings
Breaking Earnings news story on CSX »

CSX expects mid-single…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

NTRS

Northern Trust

$105.64

0.18 (0.17%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Northern Trust raises dividend 30% to 55c »

Northern Trust, holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

HOPE

Hope Bancorp

$17.52

-0.05 (-0.28%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Earnings
Hope Bancorp reports Q2 EPS 36c, consensus 37c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 07

    Nov

FULT

Fulton Financial

$16.70

-0.05 (-0.30%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Earnings
Fulton Financial reports Q2 EPS 20c, consensus 14c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 14

    Aug

CSX

CSX

$64.42

0.46 (0.72%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Hot Stocks
CSX reports Q2 operating ratio 58.6% versus 67.4% in same quarter last year »

Capital investments in Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

16:30
07/17/18
07/17
16:30
07/17/18
16:30
Options
Preliminary option volume of 17.8M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.